Avenue Therapeutics Q2 2024 net loss $2.7M; AJ201 trial topline data expected H2 2024

AVENUE THERAPEUTICS, INC.

Cash and equivalents $4.9M at June 30, 2024, up from $1.8M at Dec 31, 2023.
Net loss $2.7M ($6.43/share) for Q2 2024, compared to $4.0M ($38.74/share) in Q2 2023.
AJ201 Phase 1b/2a SBMA trial last patient visit complete; topline data expected in H2 2024.
Raised $4.4M gross proceeds from April 2024 warrant exercise; 1-for-75 reverse stock split effected.
Regained Nasdaq compliance in May 2024 after reverse split.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.